Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Market Closed 03-27 16:00:00 EDT

15.38

-0.29

-1.85%

盘后15.38

+0.000.00%

19:35 EDT

High16.07	Low15.33	Vol1.21M
Open15.75	D1 Closing15.67	Amplitude4.72%
Mkt Cap1.23B	Tradable Cap880.01M	Total Shares80.02M
T/O18.74M	T/O Rate2.12%	Tradable Shares57.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":15.38,"timestamp":1774641600000,"preClose":15.67,"halted":0,"volume":1211438,"hourTrading":{"tag":"盘后","latestPrice":15.38,"preClose":15.38,"latestTime":"19:35 EDT","volume":79738,"amount":1226350.95,"timestamp":1774654551404,"change":0,"changeRate":0,"amplitude":0.00065},"delay":0,"changeRate":-0.018506700701978247,"floatShares":57217800,"shares":80015667,"eps":-0.464974,"marketStatus":"Market Closed","change":-0.29,"latestTime":"03-27 16:00:00 EDT","open":15.75,"high":16.07,"low":15.33,"amount":18741853.227061998,"amplitude":0.047224,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.464974,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":15.67,"preHourTrading":{"tag":"盘前","latestPrice":15.6,"preClose":15.67,"latestTime":"09:28 EDT","volume":6436,"amount":100617.611468,"timestamp":1774618125016,"change":-0.07,"changeRate":-0.004467,"amplitude":0.223357},"postHourTrading":{"tag":"盘后","latestPrice":15.38,"preClose":15.38,"latestTime":"19:35 EDT","volume":79738,"amount":1226350.95,"timestamp":1774654551404,"change":0,"changeRate":0,"amplitude":0.00065},"volumeRatio":0.584279,"impliedVol":0.9665,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2621793962","title":"A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2621793962","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621793962?lang=en_us&edition=fundamental","pubTime":"2026-03-21 22:05","pubTimestamp":1774101915,"startTime":"0","endTime":"0","summary":"Event overview and recent performance\nMonte Rosa Therapeutics (GLUE) has drawn fresh attention after recent trading. The stock closed at US$15.63 and recorded a 14.5% decline over the past month, alongside a small gain over the past 3 months.\nSee our latest analysis for Monte Rosa Therapeutics.\nFor context, the recent 14.5% one-month share price decline comes after a far stronger longer run. The 1-year total shareholder return is 169.5% and the 3-year total shareholder return is 131.9%. This...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-its-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-its-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"2620247415","title":"J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247415","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247415?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:59","pubTimestamp":1773921578,"startTime":"0","endTime":"0","summary":"In a report released today, Brian Cheng from J.P. Morgan maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $30.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2620829251","title":"Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620829251","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620829251?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:31","pubTimestamp":1773840691,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMonte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 56 cents per share for the qua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4061HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2620825623","title":"Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825623","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825623?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:01","pubTimestamp":1773838860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 09:01 ET (13:01 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0},{"id":"2620375072","title":"Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620375072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620375072?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:45","pubTimestamp":1773830758,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $29.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2620420382","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420382?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:16","pubTimestamp":1773753404,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  0.4% higher.Eupraxia Pharmaceuticals  shares were up more than 1% after the company said data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.Monte Rosa Therapeutics  stock was down 1% after the company reported that it swung to a Q4 net loss as collaboration revenue declined during the period.Lensar  shares were down more than 24% after the company said it has reached an agreement with Alcon  to terminate their planned merger.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","ALC.AU","BK4082","IBB","LABU","ALC","LU2265009873.SGD","BK4534","BK4539","LNSR","BK4585","EPRX","LU1804176565.USD","GLUE","BK7094","XBI","XLV","BK4198","BK4588","BK4139"],"gpt_icon":0},{"id":"2620429675","title":"Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429675","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429675?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:25","pubTimestamp":1773746732,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7M6J4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2620175426","title":"Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620175426","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620175426?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:03","pubTimestamp":1773745431,"startTime":"0","endTime":"0","summary":"Monte Rosa published a press release reporting Q4 and full-year 2025 financial results and business updates. Q4 collaboration revenue fell 95.41% to USD 2.78 million, and R&D expenses rose 7.99% to USD 41.98 million, driven by increased spending on MRT-8102 and other development and discovery programs. Q4 net loss was USD 46.14 million, and cash, cash equivalents, restricted cash and marketable securities totaled USD 382.1 million as of Dec. 31, 2025. For FY 2025, collaboration revenue rose 63.54% to USD 123.67 million, while R&D expenses increased 16.36% to USD 141.5 million. FY 2025 net loss was USD 38.63 million, and Markus Warmuth said the company’s cash runway extends into 2029 following an upsized follow-on financing with gross proceeds of about USD 345 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2djWYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","GLUE","SG9999014013.SGD","BK4588","IE00BKPKM429.USD","BK4539","IE00BN0W2V16.EUR","NDAQ","IE00BGHQF748.EUR","SG9999014039.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","LU0314104364.USD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2620269464","title":"BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620269464","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620269464?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745246,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million\n\n\nMar 17 (Reuters) - Monte Rosa Therapeutics Q4 operating expenses USD 52.496 million.\n\nQ4 collaboration revenue USD 2.781 million\nQ4 net income USD -46.135 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX74DB4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2620942659","title":"Monte Rosa Therapeutics Q4 Net Income USD -46.135 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942659?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX74DB4C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2620642682","title":"Monte Rosa Therapeutics Q4 Operating Expenses USD 52.496 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620642682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620642682?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX74DB4C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2620426971","title":"Press Release: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426971","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426971?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745200,"startTime":"0","endTime":"0","summary":"Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial  anticipated in H2 2026. Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027. Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer  patients with AR mutations. Phase 2 study initiation of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations anticipated in Q3 2026. VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases. $345 million upsized follow-on financing further strengthens balance she","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2620493529","title":"BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2620493529","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620493529?lang=en_us&edition=fundamental","pubTime":"2026-03-17 02:03","pubTimestamp":1773684181,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, NvidiaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL6N4040NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDS.UK","ABOS","CRCD","DIPS","HCWB","PAVS","BAX","AXR","LYRA","MRAL","COGT","GLUE","NVDG","CIEN","NSA","TSQ","NEO","MOS","BHAT","NVDA","ZEPP","GPCR","INTU","HL","AU","NVDB","FPS","SOC","CUBI","ULYX","TECH","PFSI","NEM","CF","DLTR","PSA","ULY","COIG","WNW","CDE","RIOT","ALIT"],"gpt_icon":1},{"id":"2619246227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp","url":"https://stock-news.laohu8.com/highlight/detail?id=2619246227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619246227?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:42","pubTimestamp":1773675731,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers BancorpWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL6N40412P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPST","RIOX","CAST","CRCA","PAVS","ICRC","DLTR","TSQ","RIOT","CF","MU","ALIT","COGT","ULY","HCWB","MOS","NWMX","ABOS","GLUE","INTU","CIEN","CDE","ULYX","NEO","PSA","CUBI","NEM","LDOS","AU","BAX","AXR","NBIG","PFSI","COIG","NBIZ","GPCR","UAMY","SOC","RTYY","HL","WNW","ZEPP","NSA","BHAT"],"gpt_icon":1},{"id":"2619463511","title":"Monte Rosa Therapeutics Inc  expected to post a loss of 35 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463511","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463511?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:41","pubTimestamp":1773664878,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc  expected to post a loss of35cents a share - Earnings Preview Monte Rosa Therapeutics Inc GLUE.OQ GLUE.O is expected to  show a fall in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N404150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2619504214","title":"Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros","url":"https://stock-news.laohu8.com/highlight/detail?id=2619504214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619504214?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:52","pubTimestamp":1773661930,"startTime":"0","endTime":"0","summary":"March 16 (Reuters) - Monte Rosa Therapeutics Inc ::*MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TRE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nRSD407B6z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","LU1066051811.HKD","IE0002141913.USD","IE00BFXG1179.USD","LU0320765646.SGD","LU2129689514.USD","IE0002270589.USD","LU0234572021.USD","BK4585","LU1261432733.SGD","LU2089984988.USD","LU0985320562.USD","LU1032955483.USD","LU0912757837.SGD","IE00BKVL7J92.USD","IE00BLSP4239.USD","LU1023059063.AUD","IE00BGHQF631.EUR","LU2347655156.SGD","IE00BJT1NW94.SGD","LU2430703095.HKD","BK4532","LU0114720955.EUR","BK4533","JNJ","LU1066051225.USD","SG9999002224.SGD","GLUE","IE00B1BXHZ80.USD","LU2471134523.USD","IE00BJJMRZ35.SGD","LU1221951129.SGD","IE00BVYPNW00.USD","LU1221951046.USD","LU0070217475.USD","LU0124676726.USD","LU1732800096.USD","LU1280957306.USD","IE0009355771.USD","LU2133065610.SGD","LU1929549753.HKD","LU1057294990.SGD","LU1674673428.USD","LU1585245621.USD","IE00BN8TJ469.HKD","LU1196500208.SGD","LU2505996681.GBP","LU2505996509.AUD","LU1674673691.USD","LU2471134879.HKD"],"gpt_icon":0},{"id":"2619545069","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, Upstart","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545069?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:41","pubTimestamp":1773661315,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, UpstartWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL6N4040SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","ICOI","IMRA","CONX","LU1223083913.SGD","UPST","DLTR","LU0456854461.SGD","NBIG","BK4023","LU0368265764.SGD","FIAT","NBIL","NEM","NEO","LU0630314457.HKD","COIO","CONI","NBIS","NWMX","AU","COIW","COIA","PSA","UPSX","NSA","RIOX","NBIZ","MAAY","COYY","LU0266512127.USD","CONY","GLUE","BK4504","HL","BK4112","COIG","MARO","MRAL","RIOT","LU1861217088.USD","COII","NEMG","NEBX","LU0640476718.USD","SOC","RTYY"],"gpt_icon":1},{"id":"2619452077","title":"BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452077?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:10","pubTimestamp":1773659458,"startTime":"0","endTime":"0","summary":"BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer** Shares of biotech firm Monte Rosa Therapeutics GLUE.O rise 5.1% to $16.85 premarket** Co says it will start a midstage study of its experimental prostate cancer drug MRT2359 with Johnson & Johnson’s JNJ.N Erleada** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hardtotreat stage of the disease - GLUE** MRT2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&J supplying Erleada - GLUE** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says** Shares up about two fold in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4N4040WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345769128.USD","LU0345770993.USD","IE0002270589.USD","LU1430594728.SGD","LU2089984988.USD","LU1496350502.SGD","LU2750360641.GBP","IE0002141913.USD","LU0114720955.EUR","IE00BVYPNV92.GBP","LU1221951129.SGD","IE00BLSP4452.SGD","BK4588","IE00BJT1NW94.SGD","LU0320765646.SGD","LU0689626769.HKD","LU0889566641.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU1778281490.HKD","LU1983299246.USD","SG9999001440.SGD","LU1244550577.SGD","LU1935042991.SGD","SG9999002224.SGD","LU0795875169.SGD","JNJ","LU1267930813.SGD","IE0009355771.USD","LU1066053197.SGD","LU2129689514.USD","LU2430703178.SGD","LU1221951046.USD","LU2129689605.HKD","LU1066051498.USD","LU1894683264.USD","LU0912757837.SGD","BK4139","BK4533","GLUE","LU1032955483.USD","IE00BFXG1179.USD","LU0432979614.USD","LU0234572021.USD","IE00B19Z3B42.SGD","LU1066051225.USD","IE00BDGV0183.EUR","LU2133065610.SGD","BK4559","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2619529634","title":"Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619529634","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619529634?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658849,"startTime":"0","endTime":"0","summary":"Monte Rosa said it entered a clinical supply agreement with Johnson & Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide  for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson & Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLc9b2n1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689605.HKD","LU1162221912.USD","IE00B64PRP62.GBP","JNJ","IE00BN8TJ469.HKD","LU2210149790.SGD","GLUE","LU0466842654.USD","BK4581","SG9999014013.SGD","LU1221951046.USD","LU1032955483.USD","LU2468319806.SGD","LU1066051811.HKD","IE00BKPKM429.USD","LU1929549753.HKD","BK4550","LU2129689431.USD","LU1032466523.USD","LU0795875086.SGD","LU0985320562.USD","LU1732799900.SGD","LU2133065610.SGD","IE00BN0W2V16.EUR","NDAQ","IE00BVYPNV92.GBP","BK4568","IE00B19Z3B42.SGD","LU0234572021.USD","SG9999001440.SGD","LU1894683264.USD","LU1023059063.AUD","LU0795875169.SGD","IE00B2B36J28.USD","LU2471134952.CNY","LU2095319765.USD","LU1066051498.USD","SG9999002232.USD","IE00B3QW5Z07.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE0034235303.USD","BK4007","IE0009355771.USD","LU2471134523.USD","IE00BN0W2W23.USD","IE00B42XCP33.USD","LU1059921491.USD","LU2505996681.GBP","LU0792757196.USD"],"gpt_icon":0},{"id":"2619545291","title":"Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545291?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA4Z0Q19:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BLSP4452.SGD","LU1066053197.SGD","LU0795875086.SGD","LU0882574055.USD","LU1244550494.USD","LU0683600562.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","IE0002141913.USD","LU0689626769.HKD","LU1066051811.HKD","BK4534","IE00BVYPNW00.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","JNJ","BK4581","IE00BGHQF631.EUR","BK4588","LU1674673428.USD","LU0787776722.HKD","LU1261432733.SGD","LU2471134879.HKD","IE00B42XCP33.USD","IE00B19Z3581.USD","GLUE","LU0124676726.USD","IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","IE0009355771.USD","LU0795875169.SGD","LU1244550577.SGD","LU2347655156.SGD","IE00B4R5TH58.HKD","LU0792757196.USD","LU1506573853.SGD","IE00B3PB1722.GBP","LU2471134796.USD","IE0002270589.USD","BK4539","LU0234572021.USD","LU0345770993.USD","LU0912757837.SGD","LU1057294990.SGD","LU0345769631.USD","LU2430703251.USD","LU0985320562.USD","BK4585","LU2505996509.AUD","LU0070217475.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.1498},{"period":"3month","weight":-0.1105},{"period":"6month","weight":1.0534},{"period":"1year","weight":1.924},{"period":"ytd","weight":-0.0191}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.016559},{"month":4,"riseRate":0.25,"avgChangeRate":-0.206735},{"month":5,"riseRate":0.25,"avgChangeRate":-0.009649},{"month":6,"riseRate":0.5,"avgChangeRate":0.041063},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction